<- Go Home
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc., an oncology company, engages in the development and commercialization of various targeted medicines and artificial intelligence to find, fight, and follow cancer. The company’s commercial products comprise AZEDRA for the treatment of patients with unresectable locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTORfor the treatment of opioid-induced constipation. Its products also include AZEDRA, 1095, and PSMA TTC that are therapeutic agents to treat cancer; prostate-specific membrane antigen targeted imaging agents for prostate cancer; and imaging analysis technology. The company was founded in 1986 and is headquartered in New York, New York. Progenics Pharmaceuticals, Inc. operates as a subsidiary of Lantheus Medical Imaging, Inc.
Market Cap
$355.0M
Volume
980.7K
Cash and Equivalents
$29.5M
EBITDA
-$58.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$32.2M
Profit Margin
87.21%
52 Week High
$6.37
52 Week Low
$1.89
Dividend
N/A
Price / Book Value
11.60
Price / Earnings
-5.30
Price / Tangible Book Value
57.09
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$61.3M
Return on Equity
116.89%
Return on Assets
-29.18
Cash and Short Term Investments
$29.5M
Debt
$52.9M
Equity
$30.6M
Revenue
$37.0M
Unlevered FCF
-$51.5M
Sector
Biotechnology
Category
N/A